Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  2. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  3. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  4. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  5. Kragten NAM, et al. 2022. Eur J Immunol. 52:389. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  8. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  9. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  10. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  11. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  12. Marié IJ, et al. 2022. Bio Protoc. 12:e4438. PubMed
  13. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  14. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  15. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  16. Theofilatos D, et al. 2022. STAR Protoc. 3:101839. PubMed
  17. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  18. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  19. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  20. Morrow RJ, et al. 2022. Cells. 11: . PubMed
  21. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  22. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  23. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  24. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  25. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  26. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  27. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  28. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  29. Zheng J, et al. 2023. Biomater Res. 27:9. PubMed
  30. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  31. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  32. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  33. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  34. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  35. Guo A, et al. 2022. Nature. 607:135. PubMed
  36. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  37. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  38. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  39. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  40. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  41. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  42. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  43. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  44. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  45. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  46. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  47. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  48. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  49. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  50. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  51. He Y, et al. 2023. Biomolecules. 13:. PubMed
  52. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  53. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  54. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  55. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  56. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  57. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  58. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  59. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  60. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  61. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  62. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  63. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  64. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  65. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  66. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  67. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  68. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  69. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  70. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  71. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  72. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  73. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  74. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  75. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  76. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  77. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  78. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  79. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  80. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  81. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  82. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  83. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  84. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  85. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  86. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  87. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  88. Wang D, et al. 2018. Immunity. 48:659. PubMed
  89. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  90. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  91. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  92. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  93. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  94. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  95. Dong L, et al. 2021. Cancer Cell. . PubMed
  96. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  97. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  98. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  99. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  100. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  101. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  102. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  103. Li ZX, et al. 2022. Arch Virol. :. PubMed
  104. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  105. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  106. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  107. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  108. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  109. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  110. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  111. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  112. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  113. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  114. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  115. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  116. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  117. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  118. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  119. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  120. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  121. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  122. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  123. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  124. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  125. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  126. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  127. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  128. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  129. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  130. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  131. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  132. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  133. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  134. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  135. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  136. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  137. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  138. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  139. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  140. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  141. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  142. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  143. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  144. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  145. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  146. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  147. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  148. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  149. Solanki A, et al. 2018. Development. 145. PubMed
  150. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  151. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  152. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  153. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  154. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  155. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  156. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  157. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  158. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  159. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  160. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  161. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  162. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  163. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  164. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  165. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  166. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  167. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  168. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  169. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  170. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  171. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  172. He X, et al. 2021. Small. 17:e2007165. PubMed
  173. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  174. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  175. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  176. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  177. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  178. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  179. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  180. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  181. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  182. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  183. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  184. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  185. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  186. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  187. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  188. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  189. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  190. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  191. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  192. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  193. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  194. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  195. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  196. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  197. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  198. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  199. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  200. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  201. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  202. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  203. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  204. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  205. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  206. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  207. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  208. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  209. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  210. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  211. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  212. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  213. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  214. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  215. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  216. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  217. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  218. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  219. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  220. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  221. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  222. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  223. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  224. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  225. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  226. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  227. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  228. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  229. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  230. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  231. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  232. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  233. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  234. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  235. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  236. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  237. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  238. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  239. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  240. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  241. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  242. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  243. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  244. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  245. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  246. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  247. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  248. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  249. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  250. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  251. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  252. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  253. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  254. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  255. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  256. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  257. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  258. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  259. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  260. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  261. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  262. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  263. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  264. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  265. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  266. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  267. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  268. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  269. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  270. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  271. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  272. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  273. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  274. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  275. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  276. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  277. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  278. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  279. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  280. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  281. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  282. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  283. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  284. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  285. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  286. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  287. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  288. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  289. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  290. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  291. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  292. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  293. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  294. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  295. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  296. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  297. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  298. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  299. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  300. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  301. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  302. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  303. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  304. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  305. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  306. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  307. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  308. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  309. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  310. Chen B, et al. 2021. Cell. 184:6262. PubMed
  311. Smith LK, et al. 2021. Elife. 10:. PubMed
  312. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  313. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  314. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  315. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  316. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  317. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  318. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  319. Zheng Y, et al. 2022. Transl Res. :. PubMed
  320. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  321. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  322. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  323. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  324. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  325. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  326. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  327. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  328. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Spark PLUS YG581™ anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account